Back to News
Market Impact: 0.2
Jazz Pharmaceuticals Reports Positive Phase 3 Results For Ziihera Combination
Source: Nasdaq
Healthcare & Biotech
Jazz Pharmaceuticals announced updated overall survival results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera with chemotherapy, with or without Tevimbra, in adults with HER2-positive locally advanced or metastatic disease. The supplied article text provides no survival figures or details on whether the results were positive or negative.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
JAZZ0.00
More News
- Jefferies raises Zymeworks stock price target on Roche deal
- Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
- Why is Zymeworks stock surging today?
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Is an AI Research Agent?
- Bitcoin's 52% Crash Proves It's a Tech Stock: Here's What That Means for Portfolio Construction